{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T19:01:34Z","timestamp":1782586894324,"version":"3.54.5"},"reference-count":34,"publisher":"S. Karger AG","issue":"1","license":[{"start":{"date-parts":[[2012,12,14]],"date-time":"2012-12-14T00:00:00Z","timestamp":1355443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2012,12,14]],"date-time":"2012-12-14T00:00:00Z","timestamp":1355443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int Arch Allergy Immunol"],"published-print":{"date-parts":[[2013]]},"abstract":"<jats:p>&lt;b&gt;&lt;i&gt;Background:&lt;\/i&gt;&lt;\/b&gt; We examined levels of hyaluronan, a matrix glycosaminoglycan and versican, a matrix proteoglycan, in the sputum of asthmatics treated with mepolizumab (anti-IL-5 monoclonal antibody) versus placebo to evaluate the utility of these measurements as possible biomarkers of asthma control and airway remodeling. &lt;b&gt;&lt;i&gt;Methods:&lt;\/i&gt;&lt;\/b&gt; Patients with severe, prednisone-dependent asthma received either mepolizumab or placebo as described in a previously published randomized, double-blind, placebo-controlled study. We measured hyaluronan and versican levels by enzyme-linked immunosorbent assay in sputum collected before and after the 16-week treatment phase. Patients underwent a predefined prednisone tapering schedule if they remained exacerbation free, and sputum eosinophil percentage, asthma control questionnaire (ACQ) and spirometry were monitored. &lt;b&gt;&lt;i&gt;Results:&lt;\/i&gt;&lt;\/b&gt; After 6 months of mepolizumab therapy and prednisone tapering, there was a significant increase in sputum hyaluronan in the placebo group compared with baseline (p = 0.003). In contrast, there was a significant decrease in sputum hyaluronan in the active treatment group compared with placebo (p = 0.007), which correlated with improvements in percent forced expiratory volume in 1 s (FEV1%) (p = 0.001) and ACQ scores (p = 0.009) as well as a decrease in sputum eosinophils (p = 0.02). There was a nonsignificant increase in sputum versican in the placebo group (p = 0.16), a decrease in the mepolizumab group (p = 0.13) and a significant inverse correlation between versican reduction and FEV&lt;sub&gt;1&lt;\/sub&gt;% improvement (p = 0.03). &lt;b&gt;&lt;i&gt;Conclusions:&lt;\/i&gt;&lt;\/b&gt; Sputum hyaluronan values are reduced with mepolizumab therapy and correlate with improved clinical and spirometry values, suggesting this measurement may serve as a noninvasive biomarker of asthma control.<\/jats:p>","DOI":"10.1159\/000343031","type":"journal-article","created":{"date-parts":[[2012,12,14]],"date-time":"2012-12-14T08:17:01Z","timestamp":1355473021000},"page":"65-73","source":"Crossref","is-referenced-by-count":33,"title":["Sputum Hyaluronan and Versican in Severe Eosinophilic Asthma"],"prefix":"10.1159","volume":"161","author":[{"given":"Andrew G.","family":"Ayars","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard C.","family":"Altman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Potter-Perigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Radford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas N.","family":"Wight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parameswaran","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2012,12,14]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007%2Fs11882-004-0054-9"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1385%2FCBB%3A44%3A1%3A139"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2332%2Fallergolint.R-07-151"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1046%2Fj.1365-2796.1997.00170.x"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1074%2Fjbc.R100036200"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1126%2Fscience.278.5338.672"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1074%2Fjbc.274.43.30747"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1165%2Frcmb.2003-0380OC"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1365-2222.2007.02746.x"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136%2Fthx.2003.020842"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016%2FS0955-0674%2802%2900375-7"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1365-2222.2005.02334.x"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1164%2Frccm.200404-507OC"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1172%2FJCI200317974"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056%2FNEJMoa0805435"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1165%2Frcmb.2003-0380OC"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1006%2Fdbio.1993.1032"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1074%2Fjbc.274.49.34629"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1164%2Frccm.2108009"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136%2Fthx.47.12.1064"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.jaci.2011.04.006"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.4049%2Fjimmunol.0902673"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1159%2F000058782"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1165%2Frcmb.2003-0380OC"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1124%2Fjpet.301.3.830"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1155%2F2010%2F485468"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1074%2Fjbc.R100038200"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1046%2Fj.1365-2222.2002.01377.x"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1089%2F104454901750219071"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1172%2FJCI200317974"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1084%2Fjem.20071840"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1056%2FNEJMoa1014350"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1242%2Fjcs.01516"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1073%2Fpnas.93.18.9748"}],"container-title":["International Archives of Allergy and Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/343031","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/343031","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T18:20:47Z","timestamp":1745432447000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000343031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,14]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2013,4,1]]},"published-print":{"date-parts":[[2013,4,15]]}},"URL":"https:\/\/doi.org\/10.1159\/000343031","archive":["Portico"],"relation":{},"ISSN":["1018-2438","1423-0097"],"issn-type":[{"value":"1018-2438","type":"print"},{"value":"1423-0097","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,14]]}}}